HB1008

House Bill 1008 relocates the existing statute governing continuous glucose monitor (CGM) coverage in the Arkansas Medicaid program to a more appropriate subchapter of the Arkansas Code. The bill maintains the current clinical criteria for coverage, which require a patient to have type 1 or other diabetes requiring insulin more than twice daily, evidence of Level 2 or 3 hypoglycemia, or a diagnosis of glycogen storage disease type 1a. It also retains the requirement for regular six-month follow-up visits with a healthcare provider. Crucially, the bill adds a provision clarifying that Medicaid beneficiaries may obtain CGMs as a pharmacy benefit via prescription and remain eligible for associated pharmacy rebates.